Ignoring misconceptions of clinical research vs. clinical care ‘devalues participants’ dignity’

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/chaiyon021)
(Image: iStock/chaiyon021)

Related tags: Informed consent, Clinical trial

Clinical trial participants often misunderstand the differences between research and clinical care – a ‘longstanding problem’ that an enhanced informed consent process could diminish, says report.

The report, which examines the occurrence of such therapeutic misconception, was recently published​ in PLOS ONE.

Therapeutic misconception is a longstanding problem in clinical trials​,” explained Paul Christopher, MD, assistant professor of psychiatry and human behavior at Brown University and lead author of the paper.

When present, therapeutic misconception calls into question the validity of a participant's informed consent​,” he told Outsourcing-Pharma.com.

As Christopher explained, therapeutic misconception occurs when participants misunderstand the rationale behind a clinical trial, how treatment will be administered during the trial, or the extent to which a trial may benefit them.

Once we become aware that such misunderstandings are present, we have a duty to try to correct them​,” he added, noting that to ignore these misconceptions “not only devalues participants' dignity, it potentially diminishes public trust in the clinical research enterprise​.”

For the study, the researchers recruited patients for mock enrollment in a hypothetical trial in order to examine the effect of a 12-minute computerized slideshow, which emphasized the distinctions between clinical research and clinical care.

According to Christopher, participants who viewed the education intervention showed a substantial reduction in therapeutic misconception compared to those who received the standard informed consent procedure.

At the same time, receiving the additional educational intervention did not significantly deter participants from wanting to enroll​,” he explained.

The educational intervention is brief and can be incorporated into existing informed consent practices as it is currently designed, Christopher said, adding that the next step will be to test the intervention in real world clinical trials.

 

Source: PLOS ONE
doi: 10.1371/journal.pone.0184224
Reducing therapeutic misconception: A randomized intervention trial in hypothetical clinical trials
Authors: Christopher PP, Appelbaum PS, Truong D, Albert K, Maranda L, Lidz C

Related news

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars